New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2014
07:19 EDTISIS, BIIBIsis to receive $9.3M in milestone payments for ongoing Phase 2 ISIS-SMN study
Isis Pharmaceuticals (ISIS) announced that the first child in the 12 mg group was dosed in the ongoing Phase 2 study evaluating ISIS-SMNRx in children with spinal muscular atrophy. Isis also announced that the first child was dosed in an open–label extension study, which is being offered to those children with SMA who have completed dosing in Isis' previous studies. Isis will receive two milestone payments totaling $7.3M for advancements in these studies. Isis also announced that dosing in the Phase 2 study in infants with SMA is being extended. Under the extension, infants who have completed the three initially scheduled study doses will be eligible to receive an additional dose of 12 mg. Isis announced that the first infant in the study has received a fourth dose of ISIS-SMNRx approximately six months after the three initial doses were completed. For this achievement, Isis will receive a $2M milestone payment from Biogen Idec (BIIB).
News For ISIS;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 30, 2015
09:26 EDTBIIBOn The Fly: Pre-market Movers
Subscribe for More Information
09:09 EDTBIIBBiogen price target raised to $445 from $400 at RBC Capital
RBC Capital hiked its price target on Biogen as the firm thinks that the company's LINGO and Alzheimer's treatments are both reasoanble $5B-$10B opportunities. The firm keeps an Outperform rating.
08:17 EDTBIIBBiogen price target raised to $420 from $382 at RW Baird
Subscribe for More Information
08:03 EDTBIIBBiogen price target raised to $443 from $376 at Stifel
Stifel increased its price target on Biogen after listening to updates on the company's pipeline during its Q4 results conference call. The firm believes that the results of the clinical trials of Biogen's anti-LINGO in acute optic neuritis nd BIIB037 in Alzheimer’s disease were "highly positive." The firm says that the company's MS franchise is "safe and sound." It keeps a Buy rating on the shares.
06:21 EDTBIIBBiogen price target raised to $410 from $383 at Citigroup
Citigroup raised its price target for Biogen shares to $410 saying the company's 2015 guidance has upside. Citi keeps a Buy rating on Biogen following the company's Q4 results.
06:17 EDTBIIBBiogen price target raised to $399 from $370 at Leerink
Subscribe for More Information
06:07 EDTBIIBBiogen price target raised to $421 from $386 at Piper Jaffray
Piper Jaffray raised its price target for Biogen shares to $421 citing the company's "solid" Q4 results and 2015 outlook. Piper reiterates an Overweight rating on the stock.
January 29, 2015
19:14 EDTBIIBOn The Fly: After Hours Movers
Subscribe for More Information
17:07 EDTBIIBBiogen hits fresh lifetime high, levels to watch
Subscribe for More Information
16:13 EDTBIIBBiogen shares jump 5% to $371 after 2015 outlook top estimates
Subscribe for More Information
16:12 EDTBIIBBiogen reports Q4 Tecfidera revenue $916M vs. $397.6M last year
Subscribe for More Information
16:10 EDTBIIBBiogen sees 2015 EPS $16.60-$17.00, consensus $16.37
Subscribe for More Information
16:09 EDTBIIBBiogen reports Q4 EPS $4.09, consensus $3.78
Subscribe for More Information
12:00 EDTBIIBLeerink biotech analysts hold an analyst/industry conference call
Biotech Analyst Schwartz discusses Biogen Idec BIIB037 and whether 2015 will be the year when Amyloid Beta is finally validated as a disease-modifying target in Alzheimer's Disease on an Analyst/Industry conference call to be held on February 3 at 2 pm.
05:30 EDTBIIBBiogen, Fondazione Telethon and Ospedale San Raffaele announce collaboration
Subscribe for More Information
January 27, 2015
15:35 EDTBIIBNotable companies reporting before tomorrow's open
Subscribe for More Information
15:26 EDTBIIBBiogen January weekly volatility elevated into Q4 and outlook
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use